Qiagen Explores Possible Sale After New Buyer Talks: Report

Core Viewpoint - Qiagen N.V. is reviewing strategic options, including a potential sale, due to renewed takeover interest and has engaged advisers for evaluation [1][2] Group 1: Strategic Review and Potential Sale - Qiagen has held preliminary talks with multiple interested parties, including U.S.-based strategic buyers, although there is no certainty of a transaction [2] - The departure of CEO Thierry Bernard, expected once a successor is appointed, is seen as removing a key obstacle to a potential deal, making Qiagen more attractive to buyers [3] Group 2: Historical Acquisition Attempts - Qiagen has faced acquisition interest multiple times in recent years, but previous efforts did not result in a sale [4] - Notable past interest includes a high-profile approach from Thermo Fisher Scientific in 2020, which was valued at approximately $12 billion but collapsed due to opposition from an activist investor [5] - In 2021, Qiagen explored a potential combination with BioMérieux, which also did not materialize, and in 2022, discussions were reported with Bio-Rad Laboratories [6] Group 3: Financial Performance - For the third quarter, Qiagen reported adjusted earnings of 61 cents, exceeding the consensus of 59 cents, with sales of $533 million above the consensus of $525.93 million [7] - The company raised its fiscal adjusted earnings per share guidance from $2.35 to $2.38, compared to the consensus of $2.37, while affirming its sales guidance of $2.057 billion to $2.077 billion against a consensus of $2.082 billion [7] - Qiagen expects fourth-quarter adjusted earnings of 60 cents, slightly below the consensus of 61 cents per share [8] Group 4: Recent Acquisition Activity - In November 2025, Qiagen agreed to acquire Parse Biosciences for an upfront payment of approximately $225 million, with additional potential milestone payments [8] Group 5: Stock Performance - Qiagen shares experienced a decline of 4.09% to $53.18 during premarket trading, following a 16.57% increase to $55.45 the previous day [9]